MK-1084 is named as a drug or biological intervention in 3 clinical trials in our USA and China trial registers, 2 of which are recruiting. The lead sponsor is Merck Sharp & Dohme LLC. Registered phases: Phase 1, Phase 1/2 and Phase 2. Conditions studied include Metastatic Solid Tumors; Advanced Solid Tumors; Lung Neoplasm Malignant.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07252739 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (ClinicalTrials.gov ↗) Malignant Neoplasm |
Phase 2 | Recruiting |
| NCT07286149 | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (ClinicalTrials.gov ↗) Lung Neoplasm Malignant |
Phase 1/2 | Recruiting |
| NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Metastatic Solid Tumors, Advanced Solid Tumors |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Solid Tumors | 1 |
| Advanced Solid Tumors | 1 |
| Lung Neoplasm Malignant | 1 |
| Malignant Neoplasm | 1 |
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 3 |
| Register | MK-1084 trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MK-1084 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MK-1084 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.